Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (27)
Sang-Yu Ying, Yao-Ren Hu, Guo-Sheng Gao, Ke-Hong Lou & Zhen Huang. (2021) Interleukin-28B Polymorphisms Predict the Efficacy of Peginterferon Alpha in Patients With Chronic Hepatitis B: A Meta-Analysis. Frontiers in Medicine 8.
Crossref
Crossref
Laura A. Novotny, John Grayson Evans, Lishan Su, Haitao Guo & Eric G. Meissner. (2021) Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. Viruses 13:6, pages 1090.
Crossref
Crossref
Zhongyi Zhao, Zhen Qin, Linlin Zhou, Li Xiang, Jiangzhou You, Ranran Cao, Hongren Wang, Baoning Wang & Mingyuan Li. (2019) The impact of IFNL3 genotype on interferon treatment outcome in patients chronically infected with hepatitis B virus: A meta-analysis. Microbial Pathogenesis 134, pages 103598.
Crossref
Crossref
Thomas R. O'Brien, Hwai-I Yang, Sarah Groover & Wen-Juei Jeng. (2019) Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 156:2, pages 400-417.
Crossref
Crossref
Lai Wei, Heiner Wedemeyer, Yun-Fan Liaw, Henry Lik-Yuen Chan, Teerha Piratvisuth, Patrick Marcellin, Jidong Jia, Deming Tan, Wan-Cheng Chow, Maurizia R. Brunetto, Moisés Diago, Selim Gurel, Viacheslav Morozov, Hua He, Yonghong Zhu, Cynthia Wat, Bernadette Surujbally & Alexander J. Thompson. (2018) No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLOS ONE 13:7, pages e0199198.
Crossref
Crossref
Enrico Galmozzi, Floriana Facchetti, Glenda Grossi, Alessandro Loglio, Mauro Viganò, Giovanna Lunghi, Massimo Colombo & Pietro Lampertico. (2018)
IFNL4
rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients
. Liver International 38:3, pages 417-423.
Crossref
Crossref
Kessarin Thanapirom, Sirinporn Suksawatamnuay, Wattana Sukeepaisarnjaroen, Sombat Treeprasertsuk, Tawesak Tanwandee, Phunchai Charatcharoenwitthaya, Satawat Thongsawat, Apinya Leerapun, Teerha Piratvisuth, Rattana Boonsirichan, Chalermrat Bunchorntavakul, Chaowalit Pattanasirigool, Bubpha Pornthisarn, Supoj Tuntipanichteerakul, Ekawee Sripariwuth, Woramon Jeamsripong, Theeranun Sanpajit, Yong Poovorawan & Piyawat Komolmit. (2018)
Association of the S267F Variant on
NTCP
Gene and Treatment Response to Pegylated Interferon in Patients with Chronic Hepatitis B: A Multicentre Study
. Antiviral Therapy 23:1, pages 67-75.
Crossref
Crossref
Lucio Boglione, Giuseppe Cariti, Giovanni Di Perri & Antonio D'Avolio. (2016) Sequential therapy with entecavir and pegylated interferon in a cohort of young patients affected by chronic hepatitis B. Journal of Medical Virology 88:11, pages 1953-1959.
Crossref
Crossref
Bita Moudi, Zahra Heidari & Hamidreza Mahmoudzadeh-Sagheb. (2016) Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. Infection, Genetics and Evolution 44, pages 94-105.
Crossref
Crossref
Zhifeng Lin, Junguo Zhang, Xiaomin Ma, Shuo Yang, Nana Tian, Xinqi Lin, Shudong Zhou, Li Liu & Yanhui Gao. (2016) The Role of Interferon Lambda 3 Genetic Polymorphisms in Response to Interferon Therapy in Chronic Hepatitis B Patients: An Updated Meta-Analysis. Hepatitis Monthly 16:7.
Crossref
Crossref
P. Tangkijvanich, S. Chittmittraprap, K. Poovorawan, U. Limothai, A. Khlaiphuengsin, N. Chuaypen, N. Wisedopas & Y. Poovorawan. (2015)
A randomized clinical trial of peginterferon alpha‐2b with or without entecavir in patients with
HB
eAg‐negative chronic hepatitis B: Role of host and viral factors associated with treatment response
. Journal of Viral Hepatitis 23:6, pages 427-438.
Crossref
Crossref
De‐Ke Jiang, Xiaopan Wu, Ji Qian, Xiao‐Pin Ma, Jingmin Yang, Zhuo Li, Runhua Wang, Li Sun, Fang Liu, Pengyin Zhang, Xilin Zhu, Jia Wu, Kangmei Chen, Carly Conran, S. Lilly Zheng, Daru Lu, Long Yu, Ying Liu & Jianfeng Xu. (2016) Genetic variation in STAT4 predicts response to interferon‐α therapy for hepatitis B e antigen‐positive chronic hepatitis B. Hepatology 63:4, pages 1102-1111.
Crossref
Crossref
Albert Friedrich Stättermayer & Peter Ferenci. (2015) Effect of IL28B genotype on hepatitis B and C virus infection. Current Opinion in Virology 14, pages 50-55.
Crossref
Crossref
Umaporn Limothai, Rujipat Wasitthankasem, Yong Poovorawan & Pisit Tangkijvanich. (2015) Single Nucleotide Polymorphism of Interferon Lambda-4 Gene is not Associated with Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B. Asian Pacific Journal of Cancer Prevention 16:13, pages 5515-5519.
Crossref
Crossref
Hui Wang, Haiqing Wu, Shisan Bao, Xiaogang Xiang, Gangde Zhao, Kehui Liu, Fengdi Li, Yumin Xu, Baoyan An, Huijuan Zhou, Jie Lu & Qing Xie. (2015) Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population. Infection, Genetics and Evolution 31, pages 161-168.
Crossref
Crossref
Senem C. Karataylı, Mithat Bozdayı, Ersin Karataylı, Tuğba Öztürk, Abbas A. Husseini, Rabia Albayrak, Muhip Özkan, Zeynep Kalaylıoğlu, Kendal Yalçın, Kubilay Çınar, Ramazan İdilman & Cihan Yurdaydın. (2015) Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B. Liver International 35:3, pages 846-853.
Crossref
Crossref
Haiqing Wu, Gangde Zhao, Fangxing Qian, Kehui Liu, Jingdong Xie, Huijuan Zhou, Jie Xu, Yumin Xu, Yan Han, Qing Xie & Hui Wang. (2015) Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B. Liver International 35:2, pages 473-481.
Crossref
Crossref
K. Domagalski, M. Pawłowska, A. Zaleśna, M. Tyczyno, M. Skorupa-Kłaput, A. Tretyn & W. Halota. (2014) The relationship between IL-28B polymorphisms and the response to peginterferon alfa-2a monotherapy in anti-HBe-positive patients with chronic HBV infection. European Journal of Clinical Microbiology & Infectious Diseases 33:11, pages 2025-2033.
Crossref
Crossref
Louis Jansen, Annikki de Niet, Femke Stelma, Erik P.A. van Iperen, Karel A. van Dort, Marjan J. Tempelmans Plat-Sinnige, R. Bart Takkenberg, Daniel J. Chin, A.H. (Koos) Zwinderman, Uri Lopatin, Neeltje A. Kootstra & Hendrik W. Reesink. (2014) HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. Journal of Hepatology 61:4, pages 730-737.
Crossref
Crossref
Q. Zhang, M. Lapalus, T. Asselah, C. Laouénan, R. Moucari, M. Martinot‐Peignoux, I. Bieche, E. Estrabaud, S. De Muynck, N. Boyer, P. Bedossa, M. Vidaud, P. Marcellin & O. Lada. (2013)
IFNL
3 (
IL
28B) polymorphism does not predict long‐term response to interferon therapy in
HB
eAg‐positive chronic hepatitis B patients
. Journal of Viral Hepatitis 21:7, pages 525-532.
Crossref
Crossref
A. F. Stättermayer, T. Scherzer, S. Beinhardt, K. Rutter, H. Hofer & P. Ferenci. (2014) Review article: genetic factors that modify the outcome of viral hepatitis. Alimentary Pharmacology & Therapeutics 39:10, pages 1059-1070.
Crossref
Crossref
E. Galmozzi, M. Viganò & P. Lampertico. (2014) Systematic review with meta-analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon-therapy in hepatitis B infection?. Alimentary Pharmacology & Therapeutics 39:6, pages 569-578.
Crossref
Crossref
Lucio Boglione, Jessica Cusato, Sarah Allegra, Isabella Esposito, Francesca Patti, Giuseppe Cariti, Giovanni Di Perri & Antonio D’Avolio. (2014) Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Research 102, pages 35-43.
Crossref
Crossref
Toru Takahashi. (2014) Interleukin 28B genetic polymorphism and hepatitis B virus infection. World Journal of Gastroenterology 20:34, pages 12026.
Crossref
Crossref
R Bart Takkenberg, Louis Jansen, Annikki De Niet, Hans L Zaaijer, Christine J Weegink, Valeska Terpstra, Marcel GW Dijkgraaf, Richard Molenkamp, Peter LM Jansen, Maarten Koot, Vincent Rijckborst, Harry LA Janssen, Marcel GHM Beld & Hendrik W Reesink. (2013) Baseline Hepatitis B Surface Antigen (Hbsag) as Predictor of Sustained Hbsag Loss in Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2A and Adefovir. Antiviral Therapy 18:7, pages 895-904.
Crossref
Crossref
Jacinta A Holmes, Tin Nguyen, Dilip Ratnam, Neel M Heerasing, Jane V Tehan, Sara Bonanzinga, Anouk Dev, Sally Bell, Stephen Pianko, Robert Chen, Kumar Visvanathan, Rachel Hammond, David Iser, Ferry Rusli, William Sievert, Paul V Desmond, D Scott Bowden & Alexander J Thompson. (2013)
IL28B
genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α
. Journal of Gastroenterology and Hepatology 28:5, pages 861-866.
Crossref
Crossref
Nikolaus Jilg & Raymond T. Chung. (2013) One more piece in the interleukin 28B gene puzzle? The case of hepatitis B. Hepatology 57:3, pages 870-872.
Crossref
Crossref